rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ICU
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      SeaStar Medical Holding Corporation Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinanceICU
      SeaStar Medical Holding Q3 2026 Earnings Call Transcript
      Nov 11BenzingaICU
      SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
      Nov 11Yahoo FinanceICU
      SeaStar Medical Holding Corp (ICU) Q3 2026: Everything You Need To Know Ahead Of Earnings
      Nov 10Yahoo FinanceICU
      FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

      DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry (SAVE Registry) has fulfilled the post-approval study requirem

      Nov 3Yahoo FinanceICU
      ICU: QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients
      Oct 23Yahoo FinanceICU
      SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
      Oct 22Yahoo FinanceICU
      SeaStar Medical CMO receives combat nephrology award
      Oct 14Investing.comICU
      SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
      Oct 14Yahoo FinanceICU
      FDA grants breakthrough device status to SeaStar for sepsis therapy
      Oct 7Investing.comICU
      FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

      Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (F

      Oct 7Yahoo FinanceICU
      SeaStar Medical raises $3.3M through warrant exercise
      Oct 6Investing.comICU
      SeaStar Medical CMO to present at pediatric therapy conference
      Sep 29Investing.comICU
      SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
      Sep 29Yahoo FinanceICU
      SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

      Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI) SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformati

      Sep 24Yahoo FinanceICU
      SeaStar Medical at H.C. Wainwright: adult trial looms over small cap
      Sep 12Investing.comICU
      SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

      DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City. The SeaStar Medical presentatio

      Sep 10Yahoo FinanceICU

      This is the newest page. Registered accounts read further back.